Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab

BACKGROUND: Pemphigus vulgaris (PV) is a blistering, life-threatening autoimmune disease. Ethylenediaminetetraacetic acid (EDTA)-treated desmoglein (Dsg) enzyme-linked immunosorbent assay (ELISA) has recently been suggested to detect nonpathogenic antibodies. Rituximab (RTX) is now considered a firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Alaeen, Hoorieh, Toosi, Roja, Mahmoudi, Hamidreza, Balighi, Kamran, Tavakolpour, Soheil, Teimoupour, Amir, Daneshpazhooh, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938821/
https://www.ncbi.nlm.nih.gov/pubmed/31909160
http://dx.doi.org/10.1016/j.ijwd.2019.05.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938821/
https://www.ncbi.nlm.nih.gov/pubmed/31909160
http://dx.doi.org/10.1016/j.ijwd.2019.05.008

Ejemplares similares